This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring. This story matters for Finance & Markets readers tracking expo. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. ExpoNews curates and briefs the finance & markets stories that matter. Our editorial policy →